Trane Technologies Launches Innovation for Heating and Cooling With a Single Unit, While Reducing Buildings’ Carbon Footprint
Global climate innovator Trane Technologies (NYSE: TT) announced today the launch of the Sintesis™ Balance CMAF, a fully electric single unit to heat and cool buildings. The air-cooled multi-pipe solution is the latest model in the Sintesis portfolio of high-performance indoor climate systems by Trane®, the company’s HVAC brand. It is initially available for customers in Europe, Middle East, and Africa.
Sintesis Balance is a fully electric unit that delivers hot and chilled water for heating and cooling. It is ideal for buildings with dynamic temperature requirements, such as schools, hotels, hospitals, retail centers, office buildings and theaters.
“The Sintesis Balance eliminates the need for separate boiler and chiller systems, and provides flexibility to meet comfort needs across climates, seasons, use and occupancy, as well as better use of floor space,” said José La Loggia, president of Trane Technologies’ Commercial HVAC in EMEA. “It also provides highly reliable operation, temperature control and indoor air quality. Most systems in Europe use gas or oil boilers, whereas this solution is fully electric. Since buildings contribute to about 15 percent of global carbon emissions, and heating and cooling represents about 35 percent of that, Sintesis Balance is also a major step on the path to electrification and decarbonization of buildings.”
The innovation contributes to Trane Technologies’ Gigaton Challenge, a goal to reduce customers’ greenhouse gas emissions by a billion metric tons by 2030. The unit recovers and repurposes energy without generating its own carbon emissions, significantly reducing fossil fuel use over typical systems that include both a boiler and a chiller. When drawing from a grid that generates electricity from renewable sources, Sintesis Balance has potential to be a zero-emissions solution.
Sintesis Balance Sustainability by the Numbers
Trane Sintesis Balance has an average Total Efficiency Ratio of 8.2; it generates 8 kW of simultaneous cooling and heating from only 1 kW of electric power. It also delivers a Coefficient of Performance (COP) of 3.35, the highest COP among air-sourced multi-pipe unit options. (COP is a measure of how much heat the system produces per unit of energy input).
The technology’s expanded operating map allows for temperature control even in very hot or cold climates. The heating capabilities of the unit make it a good choice for building applications in regions where ambient air temperatures go down to minus 18 degrees Celsius. The unit also can heat water up to 68 degrees Celsius.
Technical features of the Trane Sintesis Balance CMAF
- Trane Adaptive Refrigerant System™ automatically optimizes refrigerant charge in each operating mode and temperature condition, delivering additional performance and efficiency gains.
- Fully electric driven CMAF multi-pipe unit doesn’t generate direct greenhouse gas emissions beyond emissions from the electricity grid. It offers up to 350 percent higher efficiency compared to most gas boilers when delivering hot water for comfort heating systems.
- Configurability with three acoustic packages and efficiency levels to meet different building application requirements.
- New generation of Trane controls technology – Tracer Symbio™ 800 controller features advanced algorithms ensuring smooth, reliable operation with low cost of ownership. In addition, it also offers six arbitration choices to optimize performances for the application.
- Tracer Symbio 800 with TD7 AdaptiView™ touchscreen provides facility managers with user-friendly control of the unit. The controller allows them to remotely manage and respond to a variety of conditions and maintain efficient operation with various pre-programmed operating modes.
For more details of on the complete Trane portfolio of solutions for EMEA, please visit www.Trane.eu.
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. Visit tranetechnologies.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200816005017/en/
Contact information
Media Contact:
Jennifer Regina, Trane Technologies
+1-630-390-8011
Jennifer.regina@tranetechnologies.com
Investors Contact:
Zachary Nagle, Trane Technologies
+1-704-990-3913
zachary.nagle@tranetechnologies.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing9.6.2025 08:00:00 EEST | Press release
Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company’s presentation is scheduled for Monday, June 16 at 16:45 ET in Room 153B. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). This announcement follows Azafaros’ recently completed and oversubscribed €132 million Series B financing round, which will support advancing nizubaglustat into pivotal clinical development. The company is on track to initiate two Phase 3 trials in GM1/GM2 gangliosidoses and NPC in 2025. Earlier this year, Azafaros reported positive topline results from its ongoing Phase 2 study evaluating n
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom